COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and body weight and comparable number of adverse events vs dulaglutide in Japanese people with type 2 diabetes
20/09/2018
Bagsværd, Denmark, 20 September 2018 - Novo Nordisk today announced the headline results from PIONEER 10, a phase 3a trial with oral semaglutide vs once-weekly subcutaneous dulaglutide, both in combination with one oral [...]
Acarix CADScor®System for early rule-out of Coronary Artery Disease (CAD) gains traction from established German users.
20/09/2018
Press release Malmö, September 20, 2018 Acarix CADScor ® System for early rule-out of Coronary Artery Disease (CAD) gains traction from established German users. Acarix AB (publ) ("Acarix"), today reported positive [...]
Avid Bioservices to Exhibit at the 17th Annual Contracting & Outsourcing Conference
20/09/2018
-- Participation at One-Day Tabletop Exhibition to Include Virtual Tour of Myford Late-Stage Clinical and Commercial Biomanufacturing Facility Highlighting Immediately Available 2,000-Liter Scale Bioreactor Capacity -- [...]
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
20/09/2018
Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease on September 25-27 in New York City Cantor Fitzgerald Global Healthcare Conference on October 1-3 in New York City CORAL GABLES, Fla., Sept. 20, 2018 [...]
Selecta Biosciences to Present at the Jefferies Gene Therapy Summit on September 27, 2018
20/09/2018
WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating [...]
Iterum Therapeutics to Present Clinical Data on Antibiotic Sulopenem at IDWeek 2018
20/09/2018
DUBLIN, Ireland and CHICAGO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, today [...]
Wave Life Sciences to Present New Data on Its DMD Exon 53 Skipping Program and Discovery Platform at Upcoming Meetings
20/09/2018
CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined [...]
OncoMed Provides Update on Navicixizumab Partnership
20/09/2018
REDWOOD CITY, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, [...]
Tetra Bio-Pharma Announces Significant Progress on Storz & Bickel Co-Development in Treating Fibromyalgia
20/09/2018
ORLEANS, Ontario, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc ., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), has made significant progress in its co- [...]
XBiotech Announces Addition of Top Dermatologist and Researcher Dr. Alice Gottlieb to its Team
20/09/2018
AUSTIN, Texas, Sept. 20, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today the addition of Alice Gottlieb, M.D., Ph.D., to its Scientific Advisory Board (SAB). Dr. Alice Gottlieb is internationally [...]
Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial
20/09/2018
Combination immunotherapy of GR-MD-02 and KEYTRUDA for all cohorts reported shows an Objective Response Rate of 50% (seven of fourteen patients). The published response rate of KEYTRUDA alone is 33% in melanoma [...]
Maverick Technology Solutions Receives Approval for Name Change and Symbol Change
20/09/2018
Concludes Final Step of Its Merger RENO, Nev., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Maverick Technology Solutions, developer and manufacturer of the ROSINBOMB brand of industry leading consumer and commercial rosin [...]
Cocrystal Pharma Completes Patient Enrollment in Phase 2a Study Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C
20/09/2018
ATLANTA, GA and BOTHELL, WA, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral [...]
Tabula Rasa HealthCare Brings Together PACE Medical Directors at 2018 Clinical Advisory Panel Meeting
20/09/2018
TRHC Clinical Pharmacists and PACE Medical Directors Gather to Learn MOORESTOWN, N.J., Sept. 20, 2018 (GLOBE NEWSWIRE) -- CareKinesis, a subsidiary of Tabula Rasa HealthCare (NASDAQ:TRHC), is hosting its 12 th Clinical [...]
Avalon GloboCare Commences Operation of its Core GMP Platform, Epicon Biotech, to Facilitate Clinical Development of Cellular Therapies
20/09/2018
FREEHOLD, N.J., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that the Company has officially commenced operation of [...]
Precipio Expands ICE-COLD PCR™ Lung Cancer Mutation Detection Offering
20/09/2018
New kit examines most relevant EGFR exons that impact therapeutic decisions for lung cancer patients NEW HAVEN, Conn., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. ( NASDAQ: PRPO ), announced today the launch of a [...]
Integrated Cannabis Company, Inc. Signs Distribution Agreement with Empower Clinics, Inc.
20/09/2018
VANCOUVER, British Columbia, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Integrated Cannabis Company, Inc. (CSE: ICAN, OTCQB: ICNAF) (“ Integrated Cannabis ”), is pleased to announce the completion of a Letter of Intent (LOI) to [...]
Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension
20/09/2018
SAN DIEGO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development of novel medicines to treat liver disease, will host an invitation-only [...]
FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program
20/09/2018
FREMONT, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions [...]

Pages